Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

作者：Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E Sanchez, Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig · 发表于：The Lancet HIV · 年份：2022 · DOI：10.1016/s2352-3018(22)00291-0 · 被引用次数：106 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV-related health complications and treatments